Stay updated on Fianlimab Combo vs Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Fianlimab Combo vs Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the Fianlimab Combo vs Pembrolizumab in Melanoma Clinical Trial page
- Check2 days agoChange DetectedA new revision entry v3.5.4 was added to the study's record history, and the previous entry v3.5.3 was removed, reflecting an update to the page's history metadata.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedThe page’s displayed software/version label has been updated from **Revision: v3.5.2** to **Revision: v3.5.3**, indicating a site update rather than a change to the trial record itself.SummaryDifference0.1%

- Check30 days agoChange DetectedRevision v3.5.2 was added and revision v3.5.0 was removed from the study record history.SummaryDifference0.1%

- Check59 days agoChange DetectedAdded Revision: v3.5.0 and removed Revision: v3.4.3 in the Record History.SummaryDifference0.1%

- Check66 days agoChange DetectedA new revision entry v3.4.3 was added and v3.4.2 was removed from the history.SummaryDifference0.1%

- Check73 days agoChange DetectedNo additions or deletions were detected; the updates relate to study status and contacts/locations within the record.SummaryDifference0.1%

Stay in the know with updates to Fianlimab Combo vs Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fianlimab Combo vs Pembrolizumab in Melanoma Clinical Trial page.